SAN DIEGO, Feb. 25, 2011 /PRNewswire/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for the three and nine months ended December 31, 2010. Net sales decreased 4% for the third quarter of fiscal year 2011 to $1,696,000 from $1,765,000 for the same period of last year. A loss of $1,202,000, $0.10 per share, was reported for the third quarter of fiscal year 2011, compared to a net loss of $294,000, $.03 per share, for the same period of the prior fiscal year.
For the nine months ended December 31, 2010, net sales increased 11% to $6,001,000 from $5,368,000 for the same period the previous fiscal year. The company reported a net loss of $1,736,000, $0.15 per share, compared to a net loss of $156,000, $0.01 per share, for the previous fiscal year. The previous fiscal year included one-time before tax settlement income of $1,250,000.
Commenting on the results of the third quarter, Mr. William Spencer, Imagenetix Chief Executive Officer said: "The loss during the quarter was driven by our advertising and promotional campaigns. Although quarterly sales to the mass market segment increased by 66% for the quarter, it was not enough to offset reductions in the wholesale and distribution segment sales. This was coupled with a significant increase in advertising and sales promotions to introduce consumers to our product line that now reaches nation-wide for Celadrin softgels and BioGuard, and throughout the west for Celadrin cream. We held many product demonstrations, offered manufacturers rebates and advertised in both print and national television media. We recognize this to be the most effective way to increase product exposure and impact sales and product recognition over the long term. In addition, we continue to analyze strategic alliances for our array of intellectual properties as well as exploring sale of non-strategic assets."
Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Celadrin®. Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.
Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2010.Imagenetix, Inc. Condensed Consolidated Statements of Operations(Unaudited)(In thousands, except per share data)Three Months EndedNine Months EndedDecember 31,December 31,2010200920102009Net sales$
5,368 Cost of sales1,2798783,4602,973Gross profit4178872,5412,395Gross profit percent24.6%50.3%42.3%44.6%Operating expenses:Selling, general and administrative1,8165733,2881,956Payroll expense272325834849Consulting expense3534341,1061,009Operating expenses 2,4411,3325,2283,814Operating loss(2,024)(445)(2,687)(1,419)Other income-316Settlement income---1,250Interest expense (44)-(158)(2)Loss before income taxes(2,068)(442)(2,844)(165)Income tax benefit(866)(148)(1,108)(9)Net loss$
(156)Loss per share:Basic and diluted$
(0.01)Weighted average common shares outstanding:Basic and diluted11,81111,01111,64511,011Imagenetix, Inc. Condensed Consolidated Balance Sheets(Unaudited)(In thousands) December 31,
March 31, 2010 2010 Assets:Current assets:Cash and cash equivalents
981Accounts receivable, net9591,049Inventories, net9881,350Prepaid expenses and other current assets282151Deferred tax asset2,034933 Total current assets4,4344,464Property and equipment, net 6789Long-term prepaid expenses918Other assets 117125 Total assets
4,696Liabilities and stockholders' equity:Current liabilities:Secured note payable to bank
-Convertible notes294-Accounts payable710997Accrued liabilities6783Customer deposits2225Contract payable7586 Total current liabilities2,1931,191Stockholders' equity 2,4343,505 Total liabilities and stockholders' equity
4,696ContactImagenetix Investor Relations
William P. Spencer(858)385-2797
Chief Executive OfficerImagenetix, Inc.Tel: (858) 674-8455
|SOURCE Imagenetix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved